Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis.

Yan S, Xu D, Sun B.

Dig Dis Sci. 2013 Jul;58(7):2107-13. doi: 10.1007/s10620-013-2570-8. Epub 2013 Jan 30.

PMID:
23361576
2.

Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis.

Yan S, Xu D, Sun B.

Dig Dis Sci. 2012 Nov;57(11):3026-31. doi: 10.1007/s10620-012-2212-6. Epub 2012 May 15.

PMID:
22585384
3.

Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma.

Ni JY, Liu SS, Xu LF, Sun HL, Chen YT.

World J Gastroenterol. 2013 Jun 28;19(24):3872-82. doi: 10.3748/wjg.v19.i24.3872.

4.

Meta-analysis on radiofrequency ablation in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.

Cao JH, Zhou J, Zhang XL, Ding X, Long QY.

J Huazhong Univ Sci Technolog Med Sci. 2014 Oct;34(5):692-700. doi: 10.1007/s11596-014-1338-5. Epub 2014 Oct 16.

PMID:
25318879
5.

Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: an up-to-date meta-analysis.

Liu Z, Gao F, Yang G, Singh S, Lu M, Zhang T, Zhong Z, Zhang F, Tang R.

Tumour Biol. 2014 Aug;35(8):7407-13. doi: 10.1007/s13277-014-1976-z. Epub 2014 Apr 29.

PMID:
24777334
6.

Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a meta-analysis of randomized-controlled trials.

Lu Z, Wen F, Guo Q, Liang H, Mao X, Sun H.

Eur J Gastroenterol Hepatol. 2013 Feb;25(2):187-94. doi: 10.1097/MEG.0b013e32835a0a07.

PMID:
23134976
7.

Combining transarterial chemoembolization with radiofrequency ablation for hepatocellular carcinoma.

Jiang G, Xu X, Ren S, Wang L.

Tumour Biol. 2014 Apr;35(4):3405-8. doi: 10.1007/s13277-013-1449-9. Epub 2013 Nov 26.

PMID:
24277379
8.

Comparative effectiveness of radiofrequency ablation with or without transarterial chemoembolization for hepatocellular carcinoma.

Kong QF, Jiao JB, Chen QQ, Li L, Wang DG, Lv B.

Tumour Biol. 2014 Mar;35(3):2655-9. doi: 10.1007/s13277-013-1349-z. Epub 2013 Nov 7.

PMID:
24197985
9.

Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis.

Wang W, Shi J, Xie WF.

Liver Int. 2010 May;30(5):741-9. doi: 10.1111/j.1478-3231.2010.02221.x. Epub 2010 Mar 18.

PMID:
20331507
10.

Transarterial chemoembolization in combination with local therapies for hepatocellular carcinoma: a meta-analysis.

Liao M, Huang J, Zhang T, Wu H.

PLoS One. 2013 Jul 3;8(7):e68453. doi: 10.1371/journal.pone.0068453. Print 2013.

11.

Medium-sized (3.1-5.0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone.

Kim JH, Won HJ, Shin YM, Kim SH, Yoon HK, Sung KB, Kim PN.

Ann Surg Oncol. 2011 Jun;18(6):1624-9. doi: 10.1245/s10434-011-1673-8. Epub 2011 Mar 29.

PMID:
21445671
12.

Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial.

Cheng BQ, Jia CQ, Liu CT, Fan W, Wang QL, Zhang ZL, Yi CH.

JAMA. 2008 Apr 9;299(14):1669-77. doi: 10.1001/jama.299.14.1669. Retraction in: DeAngelis CD, Fontanarosa PB. JAMA. 2009 May 13;301(18):1931.

PMID:
18398079
13.

Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis.

Ni JY, Liu SS, Xu LF, Sun HL, Chen YT.

J Cancer Res Clin Oncol. 2013 Apr;139(4):653-9. doi: 10.1007/s00432-012-1369-x. Epub 2013 Jan 5.

PMID:
23292073
14.

[Quality of life of primary hepatocellular carcinoma patients after radiofrequency ablation].

Wang YB, Chen MH, Yan K, Yang W, Dai Y, Yin SS.

Ai Zheng. 2005 Jul;24(7):827-33. Chinese.

PMID:
16004809
15.

[Comparison of radiofrequency ablation and transarterial chemoembolization for the treatment of a single hepatocellular carcinoma smaller than 4 cm].

Yang MJ, An SY, Moon EJ, Lee MS, Hwang JA, Cheong JY, Won JH, Kim JK, Wang HJ, Cho SW.

Korean J Hepatol. 2009 Dec;15(4):474-85. doi: 10.3350/kjhep.2009.15.4.474. Korean.

16.

Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients.

Huang ZM, Li W, Li S, Gao F, Zhou QM, Wu FM, He N, Pan CC, Xia JC, Wu PH, Zhao M.

J Immunother. 2013 Jun;36(5):287-93. doi: 10.1097/CJI.0b013e3182948452.

PMID:
23719239
17.

Radiofrequency ablation following first-line transarterial chemoembolization for patients with unresectable hepatocellular carcinoma beyond the Milan criteria.

Zhang L, Yin X, Gan YH, Zhang BH, Zhang JB, Chen Y, Xie XY, Ge NL, Wang YH, Ye SL, Ren ZG.

BMC Gastroenterol. 2014 Jan 10;14:11. doi: 10.1186/1471-230X-14-11.

18.

Transcatheter arterial chemoembolization combined with radiofrequency ablation for the treatment of hepatocellular carcinoma.

Peng ZW, Chen MS.

Oncology. 2013;84 Suppl 1:40-3. doi: 10.1159/000345888. Epub 2013 Feb 20.

19.

Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial.

Peng ZW, Zhang YJ, Chen MS, Xu L, Liang HH, Lin XJ, Guo RP, Zhang YQ, Lau WY.

J Clin Oncol. 2013 Feb 1;31(4):426-32. doi: 10.1200/JCO.2012.42.9936. Epub 2012 Dec 26.

20.

Hepatocellular carcinomas 2-3 cm in diameter: transarterial chemoembolization plus radiofrequency ablation vs. radiofrequency ablation alone.

Kim JW, Kim JH, Won HJ, Shin YM, Yoon HK, Sung KB, Kim PN.

Eur J Radiol. 2012 Mar;81(3):e189-93. doi: 10.1016/j.ejrad.2011.01.122. Epub 2011 Feb 25.

PMID:
21353417
Items per page

Supplemental Content

Write to the Help Desk